Related Experiment Video
Updated: May 26, 2026
04:30
Stimulated Single Fiber Electromyography (SFEMG) for Assessing Neuromuscular Junction Transmission in Rodent Models
Published on: March 8, 2024
Succinylcholine-induced hyperkalemia in a patient with multiple sclerosis
Michael Levine1, David F M Brown
1Department of Emergency Medicine, Section of Medical Toxicology, University of Southern California, Los Angeles, California 90033, USA.
The Journal of Emergency Medicine
|December 7, 2011
Summary
Succinylcholine can cause dangerous hyperkalemia in patients with multiple sclerosis. This case report details a life-threatening reaction, emphasizing the need for caution in neurologic patients.
Area of Science:
- Neurology
- Anesthesiology
- Pharmacology
Background:
- Succinylcholine administration is known to cause hyperkalemia in patients with various medical conditions, particularly neuromuscular disorders.
- Literature on succinylcholine-induced hyperkalemia in multiple sclerosis patients is limited.
- Multiple sclerosis is a chronic neurological disease affecting the central nervous system.
Observation:
- A case report details a 38-year-old woman diagnosed with multiple sclerosis.
- The patient experienced life-threatening hyperkalemia following succinylcholine administration.
- Succinylcholine was administered during a rapid sequence intubation procedure.
Findings:
- The administration of succinylcholine led to severe hyperkalemia in a patient with multiple sclerosis.
- This adverse event underscores a potential risk associated with succinylcholine in patients with neurological conditions.
- The case highlights the importance of considering patient-specific risk factors before administering succinylcholine.
Implications:
- Clinicians should exercise caution when using succinylcholine in patients with multiple sclerosis and other neurological diseases.
- Awareness of this potential iatrogenic complication is crucial for patient safety.
- Further research may be warranted to elucidate the mechanisms and prevalence of succinylcholine-induced hyperkalemia in multiple sclerosis.
Related Concept Videos
01:19Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
01:28Depolarizing Blockers: Mechanism of Action
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
01:21Skeletal Muscle Relaxants: Adverse Effects
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:26Anticholinesterase Agents: Poisoning and Treatment
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...